Biopure Hemopure committee review
Biopure says it has received FDA notification that the agency's Blood Products Advisory Committee will meet July 14 to review a proposed Navy trauma study of the oxygen therapeutic Hemopure [hemoglobin glutamer - 250 (bovine)]. The Navy's RESUS study of Hemopure for out-of-hospital treatment of hemorrhagic shock due to traumatic injury has been on clinical hold since June 2005. Biopure believes Hemopure "holds promise as an emergency pre-hospital treatment until patients can receive blood," the firm says May 26...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.